Stragen Announces First Subject Enrolled in Phase IIa Clinical Trial of its non-opioid analgesic STR-324
The Stragen group announced today the enrollment of the first subject to participate in a Phase IIa study of STR-324… The Stragen group announced today the enrollment of the first subject to participate in a Phase IIa study of STR-324, a first in the class of non-opioid analgesic. STR-324 is an endogenous peptide with proven […]
Continue Reading